药明康德2025年第二季度及上半年收入和利润均实现强劲增长,上半年持续经营业务收入同比增长24.2%

药明康德
28 Jul

2025年展望基于客户需求、公司 CRDMO 业务模式和管理执行的确定性,尽管面对外部不确定性,公司上调全年业绩指引。公司预计2025年持续经营业务收入重回双位数增长,增速从10-15%上调至13-17%,公司整体收入从415-430亿上调至425-435亿。公司将聚焦CRDMO核心业务,持续提高生产经营效率,有信心在2025年进一步提升经调整non-IFRS归母净利率水平。公司预计2025年资本...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10